中国人関節リウマチ患者における従来型合成抗リウマチ薬併用トファシチニブ: 無作為化対照フェーズ3試験からの患者立脚型評価
Int J Rheum Dis 2018; 21(2):402–14
This Chinese sub-population of patients with RA from ORAL Sync reported significant improvements in patient-reported outcomes (PROs), which were maintained up to 12 months from tofacitinib (TOF) treatment initiation. ORAL Sync was a randomised, Phase 3 study investigating TOF therapy in combination with csDMARDs in patients with active RA who had previously had an inadequate response to csDMARDs. To date, this is the only Phase 3 study of TOF in patients from China with RA. This analysis include...